Compare ASH & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASH | MIRM |
|---|---|---|
| Founded | 1924 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.7B |
| IPO Year | N/A | 2019 |
| Metric | ASH | MIRM |
|---|---|---|
| Price | $59.14 | $65.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $60.14 | ★ $87.55 |
| AVG Volume (30 Days) | ★ 986.9K | 545.4K |
| Earning Date | 01-27-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,824,000,000.00 | $471,794,000.00 |
| Revenue This Year | $3.29 | $53.78 |
| Revenue Next Year | $3.77 | $19.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 53.66 |
| 52 Week Low | $45.21 | $36.88 |
| 52 Week High | $75.34 | $78.55 |
| Indicator | ASH | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 65.91 | 36.47 |
| Support Level | $57.22 | $63.66 |
| Resistance Level | $61.66 | $66.77 |
| Average True Range (ATR) | 1.74 | 2.99 |
| MACD | 0.47 | -0.66 |
| Stochastic Oscillator | 78.84 | 13.68 |
Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.